210 related articles for article (PubMed ID: 32691565)
1. [Cytoreductive Partial Nephrectomy versus Cytoreductive Radical Nephrectomy for Locally T
Xiong SC; Shao YX; Hu X; Yang WX; Dou WC; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 51(4):546-551. PubMed ID: 32691565
[TBL] [Abstract][Full Text] [Related]
2. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma.
Chen J; He Q; Liu W; Li Y; Zhuang W
Clin Interv Aging; 2020; 15():431-439. PubMed ID: 32256058
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma.
Shemshaki H; Al-Mamari SA; Al-Hooti Q; Geelani IA; Al Salmi I; Narayana Kurukkal S; Kumar S; Al Julandani A; Sadeghzadeh S
Urologia; 2022 May; 89(2):160-166. PubMed ID: 35422178
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1-2M1 renal cell carcinoma.
Tian J; Zeng X; Zhu J; Guan W; Hu Z; Yang C
Transl Cancer Res; 2023 Feb; 12(2):301-309. PubMed ID: 36915574
[TBL] [Abstract][Full Text] [Related]
6. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
7. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
9. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
12. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
13. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
15. Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.
Luo Z; Jiao B; Xu Q; He W; Zhao H; Liu Y; Chen H; Guan Y; Zhang G; Jiang Z
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9657-9670. PubMed ID: 37231275
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era.
Uprety D; Bista A; Smith AL; Vallatharasu Y; Marinier DE
Anticancer Res; 2018 May; 38(5):3013-3018. PubMed ID: 29715133
[TBL] [Abstract][Full Text] [Related]
17. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
18. Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Fajkovic H; Shariat SF; Klatte T; Vartolomei MD; Lucca I; Mbeutcha A; Rouprêt M; Briganti A; Karakiewicz PI; Margulis V; Rink M; Remzi M; Seitz C; Bensalah K; Mathieu R
World J Urol; 2016 Oct; 34(10):1411-9. PubMed ID: 26879416
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
20. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy.
Lee H; Kim YJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kwak C; Kim HH; Oh JJ; Lee SC; Hong SK; Lee SE; Byun SS;
BMC Cancer; 2017 May; 17(1):364. PubMed ID: 28545466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
